MedTrace Logo

Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes

NCT00232375 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2005-10-04

No results posted yet for this study

Summary

We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a preferable outcome to reverse or preserve beta cell function in the patients with diabetes that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent autoimmune diabetes in adult (LADA).

Conditions

  • GAD Ab Positive Clinically Type 2 Diabetic Patients

Interventions

DRUG

Insulin

Sponsors & Collaborators

  • Tokyo Study Group

    lead OTHER

Principal Investigators

  • Tetsuro Kobayashi, Professor · Third Department of Internal Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-01-31
Completion
2005-01-31

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00232375 on ClinicalTrials.gov